First Bancorp reports Q2 results on July 24 with a striking reversal in options positioning that stands out against an otherwise subdued lending market.
The sharpest signal heading into the print is the collapse in the put/call ratio. It has fallen to just 0.025 — more than two standard deviations below its 20-day average of 2.61 — meaning call activity has overwhelmed puts to a degree not seen over the past year. The PCR's 52-week range runs from 0 to 3.26, and the current reading is close to the floor. That shift points to a sharply more bullish options tilt in the final sessions before earnings, a notable contrast to the defensive posture that dominated through June. The stock itself has pulled back 2.9% on the day and nearly 3% on the week to close at $62.61, even as it holds a 3% gain over the past month — suggesting the options enthusiasm has not been matched by the cash market.
The lending side tells a quieter story. Short interest at roughly 5% of free float has edged up about 10% over the past month but eased 3% on the week. Borrow costs at 0.45% are low and drifting lower. Availability is comfortable at around 420% — meaning roughly four shares remain available to borrow for every one already lent out — leaving no squeeze pressure of any consequence. The ORTEX short score has also drifted down from near 56 to 54.5 over the past two weeks, consistent with positioning that is watchful rather than aggressive.
On the fundamental debate, Raymond James raised its target to $75 and maintained a Strong Buy on July 16, the most recent analyst action and the most bullish on the Street. That target sits well above the consensus mean of $68.55. Bulls point to loan growth, asset repricing, and net interest margin expansion as the primary drivers — the bank's forward earnings growth story was cited as among the stronger ones in the regional banking cohort. Bears focus on credit quality risk and the possibility that market conditions in First Bancorp's core Southeast footprint deteriorate faster than consensus models assume. Piper Sandler, which downgraded to Neutral in February, represents the cautious end of the range with a $64 target — barely above the current price. The stock's P/E of 13x and P/B near 1.36x keep valuation from being a major catalyst in either direction. Insider activity has leaned toward selling, with the CEO, CFO, and a Chief Level Officer all reducing positions in late June at prices around $63.50 — close to where the stock trades today — though transaction sizes were modest.
Peers provided limited directional cover heading into the release. Most closely correlated names including UBSI, TRMK, and HWC were all modestly lower on the day, with weekly moves ranging from flat to down roughly 1%, suggesting sector-wide caution rather than any stock-specific read. Overall, the setup is a study in mixed signals: options traders have positioned for upside in the final stretch, short sellers are not pressing hard, and the analyst skew has nudged more constructive — but cash-market price action and recent insider sales leave a question mark over whether the Q2 numbers will validate the bullish repositioning.
See the live data behind this article on ORTEX.
Open FBNC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
